Paul R. Thompson

Mechanism of aminoglycoside antibiotic kinase APH(3')-IIIa: role of the nucleotide positioning loop.

Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300.

Selective HAT inhibitors as mechanistic tools for protein acetylation.

Regulation of the p300 HAT domain via a novel activation loop.

Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.

Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.

A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation.

Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.

Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe.

Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock?

Methyllysine analogs: rewriting the code.

Protein arginine deiminase 4: evidence for a reverse protonation mechanism.

A selective chemical probe for coenzyme A-requiring enzymes.

Peptide borono lectins (PBLs): a new tool for glycomics and cancer diagnostics.

Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis.

Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.

The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.

In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1.

Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis.

Regulation of p53 target gene expression by peptidylarginine deiminase 4.

Kinetic mechanism of protein arginine methyltransferase 1.

The protein acetyltransferase ARD1: a novel cancer drug target?

The tomato brassinosteroid receptor BRI1 increases binding of systemin to tobacco plasma membranes, but is not involved in systemin signaling.

An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4).

Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.

Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.

Characterization and inactivation of an agmatine deiminase from Helicobacter pylori.

Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.

A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation.

A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1.

Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

A fluopol-ABPP HTS assay to identify PAD inhibitors.

Mechanistic studies of agmatine deiminase from multiple bacterial species.

Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.

N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.

Boronic acid functionalized peptidyl synthetic lectins: combinatorial library design, peptide sequencing, and selective glycoprotein recognition.

Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1.

Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity.

Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability.

Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells.

Kinase consensus sequences: a breeding ground for crosstalk.

Activity-based protein profiling of protein arginine methyltransferase 1.

The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.

Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps.

Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6).

Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study.

Probing adenylation: using a fluorescently labelled ATP probe to directly label and immunoprecipitate VopS substrates.

Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo.

Potential role for PADI-mediated histone citrullination in preimplantation development.

Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation.

Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis.

Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination.

Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

The protein arginine deiminases: Structure, function, inhibition, and disease.

Activation of PAD4 in NET formation.

The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.

D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy.

Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors.

Chemical and biological methods to detect post-translational modifications of arginine.

Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus.

Targeting the arginine phosphatase YwlE with a catalytic redox-based inhibitor.

Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5.

Automethylation of protein arginine methyltransferase 8 (PRMT8) regulates activity by impeding S-adenosylmethionine sensitivity.

Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation.

Using unnatural amino acid mutagenesis to probe the regulation of PRMT1.

Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.

Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.

A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs.

Modulation of calcium-induced cell death in human neural stem cells by the novel peptidylarginine deiminase-AIF pathway.

Deimination of linker histones links neutrophil extracellular trap release with autoantibodies in systemic autoimmunity.

Pluripotency: citrullination unravels stem cells.

Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates.

Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus.

A novel role for protein arginine deiminase 4 in pluripotency: the emerging role of citrullinated histone H1 in cellular programming.

Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism.

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.

Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.

Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design.

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Inhibiting protein arginine deiminases has antioxidant consequences.

Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.

Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation.